We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.09B
1-Year Est. Return 112.84%
This Fund
S&P 500
This Quarter Est. Return
+8.83%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$1.17B
AUM Growth
+$284M
Cap. Flow
+$340M
Cap. Flow %
29%
Top 10 Hldgs %
38.67%
Holding
102
New
36
Increased
28
Reduced
14
Closed
19

Top Buys

Rank Stock Value
1
CNC icon
Centene
CNC
+$31.2M
2
CAH icon
Cardinal Health
CAH
+$29.2M
3
VERA icon
Vera Therapeutics
VERA
+$28.8M
4
CVS icon
CVS Health
CVS
+$28.1M
5
LLY icon
Eli Lilly
LLY
+$23.2M

Top Sells

Rank Stock Value
1
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
+$35M
2
NVS icon
Novartis
NVS
+$23M
3
THC icon
Tenet Healthcare
THC
+$19.3M
4
ACLX
Arcellx
ACLX
+$15.1M
5
MDT icon
Medtronic
MDT
+$13M

Sector Composition

Rank Sector Weight
1 Healthcare 96.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TVTX icon
76
Travere Therapeutics
TVTX
$5.68B
$1.74M 0.15%
+100,000
New +$1.77M
SLN
77
Silence Therapeutics
SLN
$695M
$1.38M 0.12%
+200,000
New +$2.58M
ATYR
78
aTyr Pharma
ATYR
$52.4M
$1.36M 0.12%
+375,000
New +$1.14M
KYTX icon
79
Kyverna Therapeutics
KYTX
$488M
$1.31M 0.11%
350,000
+150,000
+75% +$719K
ANRO icon
80
Alto Neuroscience
ANRO
$1.12B
$1.27M 0.11%
+300,000
New +$1.87M
CABA icon
81
Cabaletta Bio
CABA
$455M
$1.14M 0.1%
500,000
+50,000
+11% +$176K
FATE icon
82
Fate Therapeutics
FATE
$319M
$990K 0.08%
600,000
-375,000
-38% -$945K
CMPS
83
Compass Pathways
CMPS
$1.85B
$756K 0.06%
+200,000
New +$1.01M
APLT
84
DELISTED
Applied Therapeutics
APLT
– –
-800,000
Closed -$6.8M
CLDX icon
85
CALL
Celldex Therapeutics
CLDX
$3.48B
– –
-300,000
Closed -$10.2M
CRSP icon
86
CRISPR Therapeutics
CRSP
$5.23B
– –
-150,000
Closed -$7.05M
EVH icon
87
Evolent Health
EVH
$464M
– –
-200,000
Closed -$5.66M
GEHC icon
88
GE HealthCare
GEHC
$32.9B
– –
-20,000
Closed -$1.88M
IQV icon
89
IQVIA
IQV
$40.1B
– –
-20,000
Closed -$4.74M
MYGN icon
90
Myriad Genetics
MYGN
$308M
– –
-125,000
Closed -$3.42M
NGNE icon
91
Neurogene
NGNE
$714M
– –
-70,000
Closed -$2.94M
NTLA icon
92
Intellia Therapeutics
NTLA
$1.68B
– –
-100,000
Closed -$2.06M
NVS icon
93
Novartis
NVS
$294B
– –
-200,000
Closed -$23M
RVTY icon
94
Revvity
RVTY
$12.9B
– –
-30,000
Closed -$3.83M
TFX icon
95
Teleflex
TFX
$5.91B
– –
-30,000
Closed -$7.42M
TNDM icon
96
Tandem Diabetes Care
TNDM
$1.63B
– –
-150,000
Closed -$6.36M
TNGX icon
97
Tango Therapeutics
TNGX
$4.44B
– –
-200,000
Closed -$1.54M
TNYA icon
98
Tenaya Therapeutics
TNYA
$168M
– –
-2,375,000
Closed -$4.58M
TWST icon
99
Twist Bioscience
TWST
$7.72B
– –
-100,000
Closed -$4.52M
VKTX icon
100
CALL
Viking Therapeutics
VKTX
$3.94B
– –
-250,000
Closed -$15.8M
1 2 3
4
5

Similar funds

CL
CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return
ACM
Analog Century Management New York $2.09B AUM 186.85% 1-Year Est. Return
ACG
Aventail Capital Group New York $2.09B AUM 43.81% 1-Year Est. Return
NSUP
NLB Skladi upravljanje premozenja Ljubljana $2.09B AUM
TP
Third Point New York $2.08B AUM 27.04% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.08B AUM
TA
TruWealth Advisors Metairie, Louisiana $2.08B AUM 21.15% 1-Year Est. Return
AG
Avala Global New York $2.08B AUM 87.66% 1-Year Est. Return

Integral Health Asset Management's Q4 2024 Portfolio in Review

As of Q4 2024, Integral Health Asset Management held 102 positions worth $1.17B, up 32% from $889M the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Integral Health Asset Management deployed $340M of net new capital in Q4 2024, opening 36 new positions and adding to 28 existing holdings. Its largest new stake was Centene: 500,000 shares worth $30.3M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier.

On the sell side, the largest reduction was Tenet Healthcare, an estimated $19.3M trimmed.

  • Integral Health Asset Management's largest Q4 2024 buy was Centene: 500,000 shares worth $30.3M.
  • Integral Health Asset Management added most to Vera Therapeutics in Q4 2024, an estimated $28.8M increase.
  • Integral Health Asset Management's biggest Q4 2024 reduction was Tenet Healthcare, cutting an estimated $19.3M.
  • Integral Health Asset Management fully exited Longboard Pharmaceuticals, Inc. Common Stock in Q4 2024, selling an estimated $35M.
  • Integral Health Asset Management's ten largest holdings make up 39% of its $1.17B portfolio in Q4 2024.
  • Integral Health Asset Management opened 36 new positions and closed 19 in Q4 2024.
  • Integral Health Asset Management's portfolio value rose 32% quarter-over-quarter to $1.17B.

Based on Integral Health Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.